Fluticasone improves histologic eosinophilia in esophagitis

Fluticasone improves histologic eosinophilia in esophagitis
Swallowing aerosolized fluticasone improves histologic eosinophilia but does not improve dysphagia symptoms in adults with eosinophilic esophagitis, according to a study published online in the July issue of Clinical Gastroenterology and Hepatology.

(HealthDay) -- Swallowing aerosolized fluticasone improves histologic eosinophilia but does not improve dysphagia symptoms in adults with eosinophilic esophagitis (EoE), according to a study published online in the July issue of Clinical Gastroenterology and Hepatology.

To determine whether aerosolized fluticasone therapy improved symptomatic and histologic eosinophilia, Jeffrey A. Alexander, M.D., of the Mayo Clinic College of Medicine in Rochester, Minn., and colleagues conducted a randomized, double-blind, placebo-controlled trial involving adults (mean age, 37.5 years) with a new diagnosis of EoE. For six weeks, patients either swallowed 880 µg of aerosolized fluticasone (21 participants) or used a placebo inhaler twice daily (15 participants).

The researchers found that 62 percent of fluticasone-treated patients showed a complete histologic response, defined as a >90 percent reduction in mean eosinophil count, compared with none in the placebo group, in intention-to-treat analysis. In per-protocol analysis, 68 versus 0 percent had a histologic response. Eighty-one versus 8 percent of fluticasone- versus placebo-treated patients exhibited reduced eosinophil-derived neurotoxin staining. Dysphagia was reduced in 57 and 33 percent of patients treated with fluticasone and placebo, respectively (P = 0.22), in intention-to-treat analysis, and in 63 and 47 percent, respectively (P = 0.49), in per-protocol analysis. Esophageal candidiasis developed in 26 percent of fluticasone-treated patients and no patients in the group.

"In summary, this double-blind, placebo-controlled six-week trial of aerosolized fluticasone in the treatment of EoE found the treatment efficacious at decreasing esophageal eosinophilia and eosinophil activity," the authors write. "This histologic response, however, was not accompanied by a relief of symptomatic dysphagia."

One author disclosed financial ties to Meritage Pharmacia.

Abstract

Full Text

Editorial

add to favorites email to friend print save as pdf

Related Stories

Recommended for you

Spain: Ebola test drug out of supply worldwide

35 minutes ago

Doctors treating a Spanish priest who was repatriated from West Africa on Monday after being diagnosed with the Ebola virus said there were no samples of experimental drug ZMapp available in the world right ...

A multiscale approach to Ebola response

2 hours ago

The Ebola outbreak in western Africa continues to spread uncontrolled, affecting thus far five countries. On September 16th, President Obama spoke at the Centers for Disease Control and Prevention headquarters ...

Overwhelmed west Africa ramps up Ebola response

16 hours ago

West Africa intensified its response to the deadly Ebola epidemic on Sunday, with Sierra Leone uncovering scores of dead bodies during a 72-hour shutdown and Liberia announcing hundreds of new hospital beds.

Sierra Leone reaches final day of Ebola lockdown

20 hours ago

Frustrated residents complained of food shortages in some neighborhoods of Sierra Leone's capital on Sunday as the country reached the third and final day of a sweeping, unprecedented lockdown designed to ...

User comments